

Sweden Pharmaceuticals and Healthcare Report Q4 2016

<https://marketpublishers.com/r/S35C1E7794EEN.html>

Date: September 2016

Pages: 98

Price: US\$ 1,295.00 (Single User License)

ID: S35C1E7794EEN

Abstracts

Includes 3 FREE quarterly updates

BMI View: Declining government reimbursement for prescription medicines and the promotion of low-value generic medicines does not bode well for innovative drugmakers selling their products in Sweden, particularly as the government is the primary purchaser of pharmaceuticals. Over the long term, pushing costs onto a population with fewer young people to financially support the elderly will ultimately work to reduce the consumption of higher-value innovative pharmaceuticals.

Headline Expenditure Projections

Pharmaceuticals: SEK39.50bn (USD4.68bn) in 2015 to SEK39.69bn (USD4.67bn) in 2016; +0.48% in local currency terms and -0.4% in US dollar terms.

Healthcare: SEK376.26bn (USD44.62bn) in 2015 to SEK385.99bn (USD45.39bn) in 2016; +2.6% in local currency terms and 1.7% in US dollar terms

Risk/Reward Index

In BMI's Q416 Risk/Rewards Index, Sweden ranks tenth in the region. Factors such as the country's high per capita incomes and strong regulatory foundations will continue to promote per capita spending on pharmaceuticals and healthcare in general. However, the downward pressure on pharmaceutical prices will continue to be acutely felt in this

small market of fewer than 10mn people.

Latest Updates

According to LIF, the collective revenue generated by the top 15 pharmaceutical companies in Sweden increased from SEK17.42bn (USD2.08bn) in 2014 to SEK19.55bn (USD2.34bn) in 2015, with 13 of the 15 companies recording increases in revenues.

According to LIF, the collective revenue generated by the top 15 medicines experienced a 22.5% increase in 2015 - boosted by the commercialisation of Sovaldi, Harvoni and Daklinza in Sweden.

In July 2016, it was reported that Sweden has entered the race to succeed the UK as the host of the European Union's medicines agency in the aftermath of the Brexit vote.

Contents

BMI Industry View

Table: Headline Pharmaceuticals & Healthcare Forecasts (Sweden 2014-2020)

SWOT

Industry Forecast

Pharmaceutical Market Forecast

Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2012-2020)

Healthcare Market Forecast

Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)

Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)

Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)

Prescription Drug Market Forecast

Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)

Patented Drug Market Forecast

Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)

Generic Drug Market Forecast

Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)

OTC Medicines Market Forecast

Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)

Pharmaceutical Trade Forecast

Table: Pharmaceutical Trade Data And Forecasts (Sweden 2014-2020)

Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2014-2020)

Industry Risk/Reward Index

Western Europe Risk/Reward Index

Sweden Risk/Reward Index

Rewards

Risks

Regulatory Review

Intellectual Property Issues

Pricing Regime

Reimbursement Regime

Market Overview

Healthcare Sector

Table: Healthcare Resources (Sweden 2010-2015)

Table: Healthcare Personnel (Sweden 2010-2015)

Table: Healthcare Activity (Sweden 2010-2015)

Research & Development

Table: Drug Development Member Companies of SwedenBIO, 2015

Clinical Trials

Epidemiology

Competitive Landscape

Research-Based Industry

Table: Multinational Market Activity

Pharmaceutical Distribution

Pharmaceutical Retail Sector

Company Profile

AstraZeneca

Meda

Medivir

Novartis

Swedish Orphan Biovitrum (SOBI)

Demographic Forecast

Sweden Demographic Forecast

Table: Population Headline Indicators (Sweden 1990-2025)

Table: Key Population Ratios (Sweden 1990-2025)

Table: Urban/Rural Population & Life Expectancy (Sweden 1990-2025)

Table: Population By Age Group (Sweden 1990-2025)

Table: Population By Age Group % (Sweden 1990-2025)

Glossary

Methodology

Pharmaceutical Expenditure Forecast Model

Healthcare Expenditure Forecast Model

Notes On Methodology

Risk/Reward Index Methodology

Index Overview

Table: Pharmaceutical Risk/Reward Index Indicators

Indicator Weightings

I would like to order

Product name: Sweden Pharmaceuticals and Healthcare Report Q4 2016

Product link: <https://marketpublishers.com/r/S35C1E7794EEN.html>

Price: US\$ 1,295.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S35C1E7794EEN.html>